MBX Biosciences, Inc. Common Stock
- MBX
- NASDAQ
- Biotechnology
- Peptide Therapeutics
- Endocrine/Metabolic Disorders
$52.48
Today +5.79%Quote Oct 19, 2026, 08:00 PM UTC
−16.58%over the last month
Max drawdown −22.4%From 1-month high −16.6%3 months −12.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About MBX Biosciences, Inc. Common Stock
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
63
Founded
2018
Market value
$2.53B
Quote Oct 19
Floor
$50.41
3.9% below price
Resistance
$53.23
1.4% above price
Price vs analyst targets
7 analysts
Lowest target
$84.00Highest target
$150.00
$84.00Highest target
$150.00
- Price $52.48
- Average target $100.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 91% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MBXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free